AstraZeneca Investor Day Presentation Deck

ASCO GU 2022 ASCO Genitourinary Cancers Symposium 7 ● 19 abstracts with three oral presentations Two Oral presentations One Mini-oral presentation 16 Posters 19 Abstracts accepted ● ● Data highlights Lynparza + abiraterone in 1st-line mCRPC PROpel Phase III trial Lynparza + Imfinzi in 1st-line urothelial carcinoma BAYOU Phase II trial Enhertu + nivolumab in HER2+ urothelial carcinoma U105 Phase lb trial Source: ASCO GU 2022 accepted abstracts. Inclusive of externally sponsored research and partner-led trials. mCRPC = metastatic castration resistant prostate cancer; HER2+ = human epidermal receptor 2 positive. B

View entire presentation